Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions.

Neuro-oncologyยท2026
Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncologyยท2026
Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncologyยท2026
Same author

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations.

Nature communicationsยท2026
Same author

Reflecting on scientific growth and innovation as the Society for Neuro-Oncology turns 30.

Neuro-oncologyยท2025
Same author

Restraint of cancer cell plasticity by spatial homotypic clustering.

Cancer cellยท2025

Related Experiment Video

Updated: Aug 22, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

542

Targeting IDH1/IDH2 mutations in gliomas.

Macarena I de la Fuente1

  • 1Sylvester Comprehensive Cancer Center and Department of Neurology, University of Miami, Miami, Florida, USA.

Current Opinion in Neurology
|November 11, 2022
PubMed
Summary

Targeting isocitrate dehydrogenase (IDH) mutations in gliomas shows promise. Experimental therapies including small-molecule inhibitors and immunotherapies are being investigated for improved patient survival.

More Related Videos

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.2K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.9K

Related Experiment Videos

Last Updated: Aug 22, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

542
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.2K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.9K

Area of Science:

  • Oncology
  • Neuro-oncology
  • Molecular Biology

Background:

  • Somatic point mutations in isocitrate dehydrogenase (IDH) are prevalent in WHO grade 2-3 diffuse gliomas.
  • Mutant IDH (mIDH) is a significant positive prognostic factor for glioma survival.
  • mIDH mutations are crucial in glioma development (gliomagenesis).

Approach:

  • Review of experimental therapeutic strategies targeting mIDH in gliomas.
  • Investigation of small-molecule inhibitors, immunotherapies, and agents targeting mIDH-induced vulnerabilities.
  • Analysis of preclinical data and ongoing clinical trials.

Key Points:

  • Enzyme inhibitors targeting mIDH are well-tolerated in pretreated patients with preliminary clinical activity.
  • A phase 1 vaccine study for IDH1 R132H mutations showed good tolerance and immunogenicity with high survival rates.
  • Ongoing trials explore single-agent and combination therapies for mIDH gliomas in various disease settings.

Conclusions:

  • mIDH mutations are key targets for novel glioma therapies.
  • Experimental approaches including direct inhibition, immunotherapy, and epigenetic/metabolic drugs show promising results.
  • Further research is needed to optimize the timing and use of these therapies in glioma treatment.